设万维读者为首页 广告服务 技术服务 联系我们 关于万维
简体 繁体 手机版
分类广告
版主:阿飞的剑
万维读者网 > 茗香茶语 > 帖子
良心企业Gilead关于Remdesivir的消息更新
送交者: 淡紫 2020年04月05日11:50:54 于 [茗香茶语] 发送悄悄话

Gilead Sciences (NASDAQ:GILDhas been working with regulatory authorities to start additional expanded access programs for remdesivir, its investigational medicine for COVID-19, Chairman and CEO Daniel O'Day wrote on the company's website.

Such programs allow hospitals or physicians to apply for emergency use of the treatment for multiple severely ill patients at a time.

Even though the medicine isn't yet approved for use by any regulatory authorities, Gilead is taking the step of of expanding production to increase supply.

"As a result we have reduced the end-to-end manufacturing timeline from approximately one year, to around six months," O'Day wrote.

Its existing supply, including finished product and investigational medicine in final stages of production, amounts to 1.5M individual doses, which could equate to more than 140,000 treatment courses for patients.

Gilead is providing all of its existing supply at no cost to treat patients with the most severe symptoms of COVID-19.

Sets a goal of producing more than 500,000 treatment courses by October and more than 1M treatment courses by the end of the year.

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has recommended that in order to be prepared for COVID-19 becoming a seasonal occurrence, drug manufacturers should take the risk to ramp up production of therapeutics before phase 2 trials begin.


0%(0)
0%(0)
标 题 (必选项):
内 容 (选填项):
实用资讯
回国机票$360起 | 商务舱省$200 | 全球最佳航空公司出炉:海航获五星
海外华人福利!在线看陈建斌《三叉戟》热血归回 豪情筑梦 高清免费看 无地区限制
一周点击热帖 更多>>
一周回复热帖
历史上的今天:回复热帖
2019: 清明节寄托一下思念:电影"无名之
2019: 解答:药为什么杀猴子不杀皮肤
2018: 咏一个忐忑不安的度过等待诉讼的第一天
2018: 到了茶馆才发现有些可怜虫用自己的鼠目
2017: 小屋,蔻蔻:看你们聊北京胡同老房子改
2017: 含苞欲放:雄安新区
2016: 很多同学对老克的理解是不准确的
2016: 两个对火山灰毫无经验的人评论火山灰,
2015: 今天做包子有个新发现。这盘里4个一边
2015: 解释四声